PET Scan: Nursing Guide
PET imaging maps metabolic activity with radiotracers such as FDG — often paired with CT on the same scanner — to stage cancer, assess treatment response, and evaluate selected neurologic and cardiac questions. Nurses coordinate fasting and glucose validity, pregnancy and breastfeeding screening, tracer injection and uptake timing, radiation precautions, and urgent follow-up when new hypermetabolic disease or clinical deterioration appears.
Contents
Quick Facts
Key Takeaway
The main nursing priority with FDG PET/CT is protecting scan validity before tracer injection — confirm fasting and glucose status per nuclear medicine protocol, screen for pregnancy and breastfeeding, coordinate diabetic medicine
Imaging Parameters & Safety
Nurse quick-reference for imaging prep, safety screening, and transport.
Positron emission tomography (PET), often combined with CT (PET/CT)
PET uses IV radiotracer; PET/CT may include CT with or without iodinated IV contrast per protocol — follow radiology order and local policy
Uses radiotracer radiation plus CT component when PET/CT is performed; dose varies by tracer, protocol, and scanner — not specified as a single universal value in reviewed references
Radiotracer uptake often 30–60 minutes before imaging; PET/CT acquisition often about 30 minutes total per RadiologyInfo.org — longer with additional tracers or cardiac protocols
Usually supine on the PET/CT table; quiet rest during uptake phase before scanning
For whole-body FDG PET/CT, patients are generally instructed not to eat for several hours before the scan and to drink water only — follow nuclear medicine instructions
What is PET Scan?
PET Scan is a nuclear medicine imaging study that uses a radiotracer — most commonly F-18 fluorodeoxyglucose (FDG), a glucose analog — injected intravenously to show areas of increased metabolic activity. A PET scanner detects gamma emissions and creates images of organ and tissue function. When combined with CT (PET/CT), anatomic and metabolic information are fused on one examination. PET is widely used in oncology for cancer detection, staging, treatment-response assessment, and recurrence surveillance, and may also evaluate selected neurologic, cardiac, and inflammatory conditions per indication.
Overview
PET appears across oncology inpatient, outpatient infusion, and nuclear medicine pathways. Nurses rarely operate the scanner but coordinate validity-affecting preparation, IV access for tracer injection, uptake-phase monitoring, transport, pregnancy and breastfeeding screening, diabetic glucose management, post-scan hydration teaching, and timely communication when reports show new or progressive lung cancer or lymphoma metabolic activity. Because FDG reflects glucose uptake, recent eating or uncontrolled hyperglycemia can produce suboptimal images that may require rescheduling per RadiologyInfo.org.
PET complements anatomic imaging such as CT but does not replace tissue diagnosis when biopsy is indicated. Pair scheduling with symptom review — fatigue, weight loss, or new pain — and tumor-marker trends interpreted by oncology. A pending or negative PET scan does not eliminate escalation when the patient is clinically deteriorating.
Before FDG PET/CT, verify fasting status, recent oral intake, and blood glucose per nuclear medicine protocol; screen pregnancy and breastfeeding; review medicines and allergies; ensure IV access; and instruct quiet rest during uptake. After the scan, encourage hydration per instructions, monitor for tracer or contrast reactions, and escalate new neurologic deficits, respiratory distress, or report findings suggesting widespread progression per facility policy.
Radiotracer, Radiation, and FDG Metabolic Prep Safety
FDG PET/CT is low risk for most patients, but invalid prep — recent eating, uncontrolled hyperglycemia, missed tracer timing, or unscreened pregnancy — can waste a scarce appointment or delay staging decisions. Tracer and CT radiation also require appropriate screening and teaching.
- Caloric intake within the required fasting window before FDG injection
- Hyperglycemia or uncoordinated diabetes medicines before tracer administration
- Possible pregnancy or breastfeeding without risk-benefit discussion and precautions
- Proceeding with tracer despite known invalid prep because the slot is "today only"
Document: fasting status, glucose value and time, tracer administration, pregnancy/breastfeeding screen, allergies, uptake cooperation, hydration teaching, and urgent result communication.
FDG Fasting, Glucose, and Uptake-Phase Validity
FDG is a glucose analog — nursing prep directly affects whether hypermetabolic lesions can be detected. Follow nuclear medicine orders; diabetic patients often need individualized instructions.
| Prep element | Why it matters | Nursing action |
|---|---|---|
| Fasting | Eating alters FDG distribution and may require repeat scan per RadiologyInfo.org | Confirm NPO timing; clarify any oral intake before notifying nuclear medicine |
| Blood glucose | Altered glucose/insulin may adversely affect FDG PET results | Check per protocol; notify prescriber and nuclear medicine of abnormal values before tracer |
| Diabetes medicines | Insulin or oral agents may need timing adjustments per specialty plan | Document reconciliation; do not change prescribed regimens without authorization |
| Quiet uptake | Movement and talking during uptake can affect quality | Support rest in uptake room; minimize stimulation per technologist instructions |
| Appointment timing | Radiotracer decays; late arrival may require reschedule | Coordinate transport to meet scheduled tracer administration time |
What PET Scan Can and Cannot Tell You
This test can help identify:
- Areas of increased metabolic activity suggestive of malignancy, infection, or inflammation
- Cancer spread (metastatic sites) when paired with anatomic CT on PET/CT
- Treatment response or metabolic progression compared with prior PET when available
- Selected neurologic or cardiac metabolic patterns per ordered protocols
This test cannot:
- Replace histologic biopsy when tissue diagnosis is required for treatment decisions
- Detect all cancers equally — some tumors have limited FDG avidity
- Prove treatment success or failure alone — oncology integrates markers, exam, and trends
- Proceed with valid FDG interpretation after uncontrolled hyperglycemia or recent eating without protocol clearance
Pre-scan Verification for PET and PET/CT
Verify
Clarify before proceeding when:
- Patient ate or drank caloric fluids within the fasting window
- Glucose is above acceptable range or hypoglycemia treated recently without nuclear medicine guidance
- Pregnancy or breastfeeding status is unknown or positive without clearance
- Order does not match clinical indication (wrong tracer or study type)
- Iodinated contrast allergy or renal concern when contrast CT is part of PET/CT
- Patient cannot remain quiet during uptake or lie still for scanning
- Rising symptoms or tumor markers conflict with planned reassurance-only visit
Reading PET Reports With Staging, Treatment Response, and Symptoms
Integrate PET/CT with examination, symptom trends, prior PET or CT, and tumor markers. Metabolic response on PET may lag or precede anatomic change — single time points can mislead.
| Clinical context | Pair with PET findings | Nursing focus |
|---|---|---|
| Restaging on therapy | Decreased FDG uptake in known sites | Document trend; reinforce continued monitoring and oncology follow-up |
| Rising CEA or symptoms | Pending or negative PET | Escalate oncology review — do not reassure based on imaging alone |
| New hypermetabolic nodes | Reported progression or new sites | Timely prescriber notification; prepare patient for treatment discussion |
| Post-treatment inflammation | Residual uptake without clinical decline | Clarify interpretation with team; avoid false alarm or false reassurance |
PET/CT Coordination Across Oncology and Nuclear Medicine Pathways
Diagnostic safety badge: High-risk diagnostic procedure — extra safety checks required for FDG fasting, glucose validity, tracer timing, pregnancy screening, and radiation precautions.
Check-before-test protocol
- Identity + indication + tracer and PET/CT protocol verification
- Fasting and oral intake screen with glucose check per policy
- Pregnancy/breastfeeding, allergy, and diabetes medicine reconciliation
- IV access and on-time arrival for tracer administration
- Post-scan hydration, symptom teaching, and report tracking
Critical teach-back questions
- "Can you tell me why this PET scan is being done today?"
- "What fasting and drink instructions did you follow before arriving?"
- "Which symptoms — confusion, breathing trouble, severe pain, fever, or weakness — should you report immediately?"
Care coordination: oncology, nuclear medicine, radiology, pharmacy (diabetes medicines), primary prescriber, and rapid response when acute complications occur.
Why PET Scan is Ordered
Clinicians order PET or PET/CT when metabolic and anatomic information will answer staging, treatment-response, recurrence, or selected non-oncology questions. Indication and tracer type determine preparation and timing.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Oncology staging and restaging (e.g., lung, lymphoma, colorectal pathways) | Where is metabolically active disease and has it spread? | Guides treatment planning, radiation fields, and surgical candidacy discussions with oncology. |
| Assess treatment response or evaluate suspected recurrence | Is disease responding, stable, or progressing metabolically? | Supports hold-or-continue treatment decisions when paired with examination and tumor markers. |
| Selected neurologic evaluation (e.g., dementia, seizure workup per protocol) | Is there focal metabolic pattern suggesting structural or degenerative disease? | Supports neurology referral and further MRI or CSF testing when clinically indicated. |
| Selected cardiac viability or perfusion questions (institutional protocols) | Is myocardium viable or ischemic per ordered cardiac PET protocol? | Supports cardiology decisions regarding revascularization when ordered as part of a defined pathway. |
Contraindications and Precautions
Absolute contraindications depend on tracer, pregnancy status, and institutional policy. Nurses focus on identifying pregnancy, breastfeeding, uncontrolled hyperglycemia, recent eating before FDG PET, and contrast allergy when iodinated CT contrast is planned — clarifying with nuclear medicine and the prescriber before tracer injection.
- Patient ate or drank caloric fluids within the required fasting window for FDG PET — may invalidate distribution and require reschedule per nuclear medicine.
- Blood glucose above institutional acceptable range for FDG PET — clarify correction or reschedule per protocol; altered glucose and insulin levels may adversely affect FDG uptake per RadiologyInfo.org.
- Possible pregnancy or breastfeeding without risk-benefit discussion — radiation and tracer excretion precautions apply per institutional policy.
- Late arrival may miss scheduled tracer dose time — radiotracer decays quickly; appointment timing matters per RadiologyInfo.org.
- Iodinated CT contrast allergy or renal impairment when diagnostic CT with contrast is ordered — follow institutional contrast screening policy.
- Anxiety, pain, or inability to lie still during uptake or scanning may increase motion artifact or require support per nuclear medicine.
- Anaphylaxis or severe reaction to radiotracer or iodinated contrast during or after the study.
- Verbal or written report of widespread new hypermetabolic disease or rapid progression with declining functional status or vital signs.
- Clinical deterioration with pending or prior negative PET — escalate per facility policy; PET does not rule out all pathology.
Patient Preparation
Preparation directly affects FDG PET validity. Follow the nuclear medicine order, tracer-specific instructions, and institutional checklist — diabetic patients often receive individualized guidance.
Pre-test checksList all medicines for nuclear medicine review. Diabetic patients may need coordinated insulin or oral hypoglycemic timing per specialty instructions — do not independently change prescribed diabetes medicines unless authorized. Document reconciliation and any holds per protocol.
Where the test is performed
This page is a Tests & Diagnostics guide for PET Scan. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
PET Scan is usually performed or finalized outside the bedside nursing procedure library (for example central laboratory or imaging services). This guide focuses on orders, preparation that affects validity, interpretation, and escalation.
Use the preparation, results, and nursing responsibility sections below for safety checks, interpretation, escalation, and documentation — not equipment operation or departmental imaging protocols.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
PET results describe metabolic activity patterns (often reported as FDG-avid or hypermetabolic areas) fused with CT anatomy on PET/CT. Nurses integrate reports with examination, symptoms, prior imaging, and trends on a comprehensive metabolic panel or tumor markers — not the report alone.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| No acute critical finding / as expected for indication | No abnormal FDG uptake or metabolically active disease identified (report wording varies) | May support treatment response or lower suspicion for active sites but must fit clinical context | Continue oncology surveillance plan; escalate if symptoms or markers worsen |
| Equivocal / indeterminate finding | Indeterminate, physiologic, or post-treatment inflammatory uptake | May require correlation with prior PET, MRI, or biopsy per radiology recommendation | Clarify with prescriber; avoid false reassurance when symptoms progress |
| Abnormal finding — clinically significant | New or increasing hypermetabolic lesions or widespread FDG-avid disease | May indicate progression, recurrence, or untreated active malignancy — often prompts treatment change | Notify oncology per policy; prepare patient for likely treatment discussion and further tests |
| Not applicable | Decreased uptake compared with prior PET in known sites (response pattern) | May suggest treatment response when paired with clinical improvement and markers | Document trend; continue monitoring per oncology plan and evaluate symptoms |
Urgent Findings and Escalation
PET does not use laboratory critical values, but certain reported findings and clinical combinations require urgent nursing action independent of routine outpatient scheduling.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Reported widespread new hypermetabolic disease with rapid clinical decline | Verbal or written PET/CT suggesting extensive progression with worsening function or vitals | Notify oncology and prescriber immediately per critical-result policy; coordinate urgent follow-up |
| Suspected brain metastasis or CNS progression on PET report | New hypermetabolic brain lesions with neurologic symptoms | Escalate neurology/oncology urgently; maintain neurologic monitoring per protocol |
| Severe tracer or contrast reaction | Anaphylaxis, airway compromise, or shock during or after study | Activate emergency response per facility policy; document event and treatments given |
Stop routine workflow and escalate according to facility policy when the patient develops anaphylaxis, acute neurologic change, respiratory distress, uncontrolled pain with new functional decline, or when PET suggests extensive progression while the patient is clinically deteriorating — regardless of prior negative imaging.
Factors Affecting Results
FDG PET interpretation and image quality may be affected by glucose level, recent eating, infection or inflammation, recent chemotherapy, timing relative to treatment, and patient movement.
- Physiologic FDG uptake in brain, heart, urinary tract, or bowel may mimic pathology without correlation
- Inflammation, infection, or recent surgery can produce hypermetabolic areas unrelated to malignancy
- Recent chemotherapy or radiation may cause inflammatory uptake before true response is clear
- Small lesions, low-grade tumors, or hypometabolic histologies may have limited FDG avidity
- Hyperglycemia or recent eating can reduce lesion conspicuity and produce suboptimal scans
- Very early recurrence or tiny nodal disease may be below PET resolution depending on timing and protocol
- Uncontrolled hyperglycemia or recent caloric intake before FDG injection
- Recent infection, fever, or high-dose steroids altering inflammatory uptake
- Patient movement or talking during uptake phase increasing artifact
PET shows metabolic activity, not histologic diagnosis — biopsy may still be required. FDG PET is not equally sensitive for all tumor types. Combined PET/CT adds CT radiation and may include iodinated contrast risks when ordered. All results require clinical context and oncology interpretation.
Nursing Responsibilities
Nursing care emphasizes valid FDG preparation, tracer safety screening, uptake-phase support, post-scan hydration teaching, and timely oncology communication when reports change management.
Before the TestDocumentation
Documentation supports oncology continuity, tracer safety, and medicolegal traceability.
“FDG PET/CT restaging completed 1130. Two identifiers verified. Fasting confirmed since 0500; point-of-care glucose 102 mg/dL before tracer. Pregnancy screen negative. Allergies reviewed (no iodinated contrast ordered). IV tracer administered without immediate reaction; quiet uptake 45 minutes per protocol. Patient tolerated scan; encouraged oral fluids post procedure. Verbal preliminary read communicated to oncology fellow; formal report pending. Patient instructed to report fever, neurologic changes, rash, dyspnea, or worsening pain before follow-up visit.”
- Indication, tracer type, fasting and glucose verification with time documented
- Pregnancy/breastfeeding screen, allergies, and contrast status if PET/CT
- Tracer administration time, uptake duration, and patient cooperation during rest
- Immediate complications, hydration teaching, and post-scan instructions given
- Critical or urgent result communication with read-back per policy
- Oncology follow-up plan and symptom reporting reinforced
Patient and Family Education
Use plain language about tracer injection, quiet waiting period, radiation exposure, and symptoms that require immediate reporting.
PET Scan NCLEX practice questions
Practice NCLEX-style clinical judgment focused on PET Scan safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: FDG PET/CT restaging — outpatient nuclear medicine
- Indication: Non-small cell lung cancer on pembrolizumab; evaluate treatment response
- Timing: Scheduled 0800 tracer slot; fasting since midnight requested
- Related orders: CEA trend rising; CMP last week; oncology follow-up Thursday
- Result: Tracer not yet given; morning glucose 248 mg/dL; patient ate toast at 0630
- Trend / prior value: CEA 4.2 → 6.8 ng/mL over 8 weeks; fatigue increasing; weight stable
- Pending tests: Formal PET/CT report and oncology treatment plan
- Vital signs: T 36.8 °C, HR 88/min, BP 128/74, RR 16, SpO₂ 97% on room air
- Symptoms: Increased fatigue; dry cough unchanged; no chest pain or neurologic deficits
- Focused assessment: Alert; mild exertional dyspnea; lungs with chronic scattered wheeze; no focal neurologic deficit
- Preparation notes: Patient reports “only a small breakfast” before arrival; insulin glargine taken at usual time; anxiety about tracer injection
- Collection events: Nuclear medicine notified of late breakfast; IV line patent; uptake room not yet started
- Teaching gaps / safety concerns: Hyperglycemia and recent oral intake before FDG; rising CEA with worsening fatigue; tracer timing window
Answer key & rationale
Frequently Asked Questions
FAQ
What is a PET scan used for in nursing practice?
PET imaging shows metabolic activity using radiotracers — often FDG — and is commonly used with CT (PET/CT) to detect cancer, determine spread, assess treatment response, evaluate recurrence, and address selected neurologic or cardiac questions per RadiologyInfo.org.
Why must patients fast before FDG PET/CT?
Eating can alter FDG distribution and produce suboptimal images that may require repeating the scan on another day per RadiologyInfo.org. Patients are generally instructed not to eat for several hours and to drink water only — follow nuclear medicine instructions.
How does blood glucose affect FDG PET?
Altered blood sugar or insulin levels may adversely affect FDG PET results per RadiologyInfo.org. Nuclear medicine protocols often require glucose checks and may reschedule or correct hyperglycemia before injection — follow institutional policy rather than a universal numeric threshold in this guide.
Does PET diagnose cancer by itself?
PET identifies areas of increased metabolic activity that may represent malignancy, infection, or inflammation — tissue biopsy or specialist correlation is often still required for definitive histologic diagnosis when suspicion is high.
What should nurses teach after PET/CT?
Encourage hydration to help clear tracer per instructions unless contraindicated; review breastfeeding guidance if applicable; teach symptoms requiring urgent reporting (rash, breathing difficulty, neurologic changes); and explain that formal results are reviewed by radiology and the treating team.
Can pregnant or breastfeeding patients have PET scans?
Patients should tell the team if pregnancy or breastfeeding is possible. Radiation and tracer excretion require risk-benefit discussion and institutional precautions per RadiologyInfo.org radiation safety guidance — defer or modify imaging per policy when pregnancy is confirmed.
When should nurses escalate despite a scheduled PET appointment?
Escalate according to facility policy for uncontrolled hyperglycemia or recent eating before FDG tracer, possible pregnancy without clearance, severe reaction to tracer or contrast, acute neurologic change, or clinical deterioration with report suggesting extensive progression.
References
References
-
Radiological Society of North America. PET/CT — Positron Emission Tomography/Computed Tomography. RadiologyInfo.org; reviewed March 24, 2025.https://www.radiologyinfo.org/en/info/pet
-
U.S. National Library of Medicine. Positron Emission Tomography (PET). MedlinePlus.https://medlineplus.gov/ency/article/003827.htm
-
Society of Nuclear Medicine and Molecular Imaging. What is PET?. SNMMI.https://www.snmmi.org/Patient-Resources/What-is-PET
-
American College of Radiology. ACR Appropriateness Criteria. ACR.https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria
-
U.S. Food and Drug Administration. Radiation-Emitting Products — PET Scans. FDA.https://www.fda.gov/radiation-emitting-products/medical-imaging/positron-emission-computed-tomography-pet-scans
-
National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE Guideline NG12.https://www.nice.org.uk/guidance/ng12
-
Centers for Disease Control and Prevention. How Is Cancer Diagnosed?. CDC.https://www.cdc.gov/cancer/diagnosis-treatment/diagnosis.html
-
National Cancer Institute. Imaging Tests to Find Cancer. NIH.https://www.cancer.gov/about-cancer/diagnosis-staging/imaging-tests-to-find-cancer
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for PET Scan.
Policies: Medical Review Process · Editorial Policy · Correction Policy